Union Science and Technology Minister Dr. Jitendra Singh on Saturday, 20 June 2026 highlighted a string of landmark achievements in India's biotech and pharmaceutical sector, pointing to the country's first DNA vaccine, two purely indigenous antibiotics, and a genetic cure option for haemophilia as evidence of a healthcare ecosystem that is 'turning increasingly indigenous, but with global potential.'

Context

In his post on X, Dr. Singh stated: 'India's healthcare ecosystem is turning increasingly indigenous, but with global potential. We gifted the world with the first DNA Vaccine for Covid, and more recently for the first time came out with two purely indigenous antibiotics and a genetic cure option for Haemophilia.' The statement clusters several distinct milestones to build a narrative of self-reliance in critical medicines and advanced therapies.

The reference to the world's first DNA vaccine for Covid points to ZyCoV-D, the plasmid DNA vaccine developed by Zydus Cadila that received emergency use authorisation from Indian regulators in August 2021. Its approval marked a global first in DNA vaccine technology reaching clinical deployment, and it remains a flagship example cited by the government in discussions on indigenous biotech capability.

Policy Backdrop

The minister's remarks sit squarely within the framework of the Atmanirbhar Bharat Abhiyan, the self-reliance initiative launched in May 2020 to reduce import dependence across critical sectors including pharmaceuticals and biotechnology. Supply-chain disruptions during the Covid-19 pandemic sharpened the political and policy urgency behind indigenous drug and vaccine development.

The National Biopharma Mission, approved in 2017, had already set the institutional groundwork by channelling public funding into affordable indigenous biopharmaceutical innovation. Increased allocations to the Department of Biotechnology and the Indian Council of Medical Research (ICMR) over the past decade have supported the pipeline of products that Dr. Singh is now citing as proof of delivery.

The two indigenous antibiotics and the haemophilia gene therapy option represent newer entries in that pipeline. Haemophilia, a hereditary bleeding disorder affecting thousands of patients across India, has historically required expensive imported clotting-factor concentrates, making a domestic genetic therapy option — if it clears regulatory scrutiny — a significant development for patient access and affordability.

Stakeholders and Impact

For Indian biotech firms, the minister's public endorsement of these products signals continued government backing for indigenous innovation and potential facilitation at the regulatory level through the Central Drugs Standard Control Organisation (CDSCO). Domestic pharmaceutical manufacturers stand to gain from any policy preference for indigenously developed molecules in public procurement.

Patients living with haemophilia and those requiring antibiotic treatment for drug-resistant infections represent the most direct beneficiaries if the cited products receive full approvals and are made available at scale. Advocacy groups have long pressed for affordable domestic alternatives to imported biologics, and a genetic cure option would mark a qualitative shift in treatment paradigm.

On the global stage, India's track record — anchored by its role as a major vaccine supplier during the pandemic — gives these announcements credibility in conversations about technology transfer and WHO prequalification for new products.

What's Next

Regulatory watchers will focus on CDSCO decisions regarding the dossiers for the two indigenous antibiotics and the haemophilia gene-therapy candidate. WHO prequalification, if pursued, would open export markets and reinforce India's positioning as a global supplier of affordable advanced therapies.

If the government moves to integrate these products into national health programmes — such as the National Haemophilia Programme — the impact on patient access and import substitution could be substantial. The minister's statement is likely to be followed by formal announcements from the Department of Biotechnology as regulatory milestones are reached.